Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

Summary

The primary purpose of this study is to determine whether empagliflozin, a medication in a class known as sodium-glucose cotransporter-2 inhibitors (SGLT2) inhibitors, may reduce symptoms of depression. Since this medication helps the body make metabolites known as ketone bodies which can serve as an alternate energy source for the brain, the investigators can also test whether ketone bodies help with depressed mood.

Eligibility

Inclusion Criteria:

* Provide written informed consent, as approved by the NYU Institutional Research Ethic Board (IRB).
* Patients ages 18-65;
* Current/acute Major Depressive Disorder (MDD) diagnosis, per MINI psychiatric interview;
* At least moderate severity of depression (Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 20 at initial screen);

Exclusion Criteria:

* DSM-5 diagnosis of Bipolar disorders, Cyclothymia, Schizoaffective disorder, Schizophrenia; any psychotic disorder or affective psychosis;
* Subjects that have had more than two failures of adequate anti-depressant trials in the current MDD episode;
* Subjects on psychotropic medications other than SSRIs, NDRIs, SNRIs, or mirtazapine (occasional use of sleep agents, equivalent to lorazepam 1 mg or zolpidem 10 mg, will be allowed);
* Those that have previously been on SGLT2 inhibitors;
* A significant history of non-adherence to treatments;
* History of neurologic / seizure disorder;
* A significant history of non-adherence to treatments;
* History of dementia/cognitive dysfunction (MOCA \< 22);
* A primary diagnosis of a personality disorder, in the opinion of the screening clinician;
* DSM-5 substance use disorder (drug/alcohol) active within the past 12 months, or positive urine toxicology at screening;
* History of diabetic ketoacidosis;
* History of recurrent genital mycotic infection;
* GFR \<45;
* HgA1c.\>8.0%
* History of an allergic reaction to an SGLT2 inhibitor.
* Pregnancy or lactation (women of reproductive age, ie \<50 years old, should be on licensed hormonal or barrier method contraception).
* Any known pancreatic disease resulting in insulin deficiency (T1D, history of pancreatitis, pancreatic surgery);
* History of liver or kidney disease;
* Hypersensitivity to empagliflozin or any of the excipients in JARDIANCE.

Conditions2

Interventions1

Locations1 site

Find trials near these locations

Related trials

• Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes — McGill University Health Centre/Research Institute of the McGill University Health Centre
• Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin — Celltrion
• Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia. — EMS
• Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes — Mostafa Bahaa
• Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus — EMS
• Feasibility Trial for a Right Ventricular Failure Platform Trial — University of Alberta
• Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study — Getz Pharma
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Boehringer Ingelheim

Browse More Trials